• Margin recovery trajectory: Consolidated EBITDA margins are projected to return to FY25 levels in FY27 as one-time M&A and forex costs fall off. PAT margins are also expected to accelerate, though non-cash amortization charges will continue at current levels before declining in FY28.
• BioPharm integration progress: BioPharm delivered sequential growth exceeding 15%, with its integration and transition fully completed effective February. The acquisition is expected to sustain its growth momentum and positively contribute to FY27 margins.
• FY27 revenue outlook: Management expects consolidated organic and inorganic revenue growth to accelerate in FY27, surpassing the 23% growth rate recorded in FY26.
• Client portfolio expansion: The company has 91 active clients, with 53 crossing the $1 million revenue milestone. Growth was supported by the addition of 3 new million-dollar-plus client logos during the quarter.